#1 Clinical Trials Search in Europe

RIMIDUCID

RIMIDUCID is an innovative drug being investigated in numerous clinical trials as a safety mechanism for cellular therapies, particularly in stem cell transplants and CAR-T cell treatments. It functions as a “safety switch” that can selectively eliminate engineered cells when severe side effects occur. This article explores how RIMIDUCID is being used in clinical trials for various conditions, including blood cancers, multiple myeloma, and solid tumors. By understanding its role in these treatments, patients can gain valuable insights into emerging therapeutic approaches that balance efficacy with safety.

# Rimiducid: A Safety Switch Medication for Advanced Cellular Therapies Table of Contents – [What is Rimiducid?](#what-is-rimiducid) – [How Rimiducid Works](#how-rimiducid-works) – [Medical Conditions Treated with Rimiducid](#medical-conditions-treated-with-rimiducid) – [Rimiducid in CAR-T Cell Therapy](#rimiducid-in-car-t-cell-therapy) – [Rimiducid in Stem Cell Transplantation](#rimiducid-in-stem-cell-transplantation) – [Safety Profile and Side Effects](#safety-profile-and-side-effects) – [Current Research and Clinical Trials](#current-research-and-clinical-trials) – [Future Directions](#future-directions) What is Rimiducid? Rimiducid (also known by its alternative name AP1903) is not a standard anti-cancer drug but rather a specialized medication designed to work as a “safety switch” in certain cellular therapies. It is administered to patients who have received genetically modified cells as part of their treatment for various conditions, particularly blood cancers and other disorders[1]. Rimiducid serves as a critical safety mechanism in advanced cellular therapies. When patients receive genetically modified cells (such as T cells), these cells are engineered to include a self-destruct mechanism called a “safety switch” or “suicide gene.” If these modified cells cause severe side effects like Graft-versus-Host Disease (GvHD), rimiducid can be administered to activate this safety switch, causing the problematic cells to self-destruct through a process called apoptosis[2]. This innovative approach allows doctors to have better control over cellular therapies, potentially making these treatments safer for patients. How Rimiducid Works Rimiducid functions through a precise molecular mechanism targeting genetically modified cells: 1. **Activation of the Safety Switch**: Rimiducid is administered intravenously, typically at doses of 0.4 mg/kg, though lower doses (0.1 mg/kg and 0.05 mg/kg) are also being investigated in some trials[3]. 2. **Inducing Apoptosis**: Once administered, rimiducid binds to a special protein called inducible caspase 9 (iCasp9) that has been engineered into the modified cells. This binding causes the protein to activate, triggering a cascade of cellular events that lead to apoptosis (programmed cell death) of the modified cells[4]. 3. **Targeted Cell Elimination**: This mechanism allows for selective elimination of only the genetically modified cells that contain the safety switch, while leaving other healthy cells in the body unaffected[5]. The beauty of this system is its specificity – rimiducid only affects cells that have been specifically engineered to respond to it, providing a precise way to control cellular therapies if they begin causing harmful side effects. Medical Conditions Treated with Rimiducid Rimiducid is not a primary treatment for any disease but rather acts as a safety component in cellular therapies for various conditions. Based on clinical trial data, these conditions include: # Blood Cancers – **Acute Lymphoblastic Leukemia (ALL)**: A cancer of lymphocyte blood cells that affects both children and adults[6]. – **Acute Myeloid Leukemia (AML)**: A cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells[7]. – **Non-Hodgkin Lymphoma**: A group of blood cancers that includes all types of lymphoma except Hodgkin lymphomas[8]. – **Multiple Myeloma**: A cancer of plasma cells that accumulate in the bone marrow[9]. – **Myelodysplastic Syndromes (MDS)**: A group of disorders caused by poorly formed or dysfunctional blood cells[10]. # Solid Tumors – **Metastatic Prostate Cancer**: Advanced prostate cancer that has spread to other parts of the body[11]. – **Various Advanced Solid Tumors**: Including breast cancer, colorectal cancer, and others in experimental treatments[12]. # Non-Malignant Conditions – **Primary Immunodeficiency Disorders**: Inherited conditions that affect the immune system[13]. – **Hemoglobinopathies**: Genetic disorders affecting hemoglobin structure, such as sickle cell anemia[8]. – **Aplastic Anemia**: A condition where the body stops producing enough new blood cells[2]. – **Inherited Metabolic Disorders**: Conditions where the body cannot properly convert food to energy[4]. – **Systemic Lupus Erythematosus (SLE)**: An autoimmune disease in which the immune system attacks the body’s tissues and organs[14]. Rimiducid in CAR-T Cell Therapy Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy where a patient’s T cells are modified to better recognize and attack cancer cells. Rimiducid plays a crucial role in enhancing the safety of these advanced treatments. # How CAR-T Cell Therapy Works with Rimiducid In CAR-T cell therapy with rimiducid safety systems: 1. **T Cell Collection**: Doctors collect T cells from the patient’s blood through a process called apheresis[9]. 2. **Genetic Modification**: These T cells are genetically modified in a laboratory to express: – A chimeric antigen receptor (CAR) that targets specific proteins on cancer cells – A safety switch gene (often the inducible caspase 9 or iCasp9 gene) that responds to rimiducid[5] 3. **Cell Expansion**: The modified T cells are grown in large numbers in the laboratory. 4. **Infusion**: The patient receives the modified CAR-T cells through an IV infusion. 5. **Monitoring and Safety Management**: If the patient develops severe side effects from the CAR-T cells (such as cytokine release syndrome or neurotoxicity), rimiducid can be administered to activate the safety switch and eliminate some or all of the CAR-T cells[15]. # Examples of CAR-T Products Using Rimiducid Several experimental CAR-T products incorporate rimiducid-responsive safety switches, including: – **P-BCMA-ALLO1**: Targets B-cell maturation antigen in multiple myeloma[16]. – **P-CD19CD20-ALLO1**: Targets CD19 and CD20 proteins in B-cell malignancies[17]. – **P-PSMA-101**: Targets prostate-specific membrane antigen in prostate cancer[11]. – **BPX-601**: Targets PSCA (prostate stem cell antigen) in solid tumors[12]. – **P-MUC1C-ALLO1**: Targets MUC1C in various solid tumors[18]. Rimiducid in Stem Cell Transplantation Stem cell transplantation is a procedure in which healthy blood-forming stem cells are used to replace damaged or diseased bone marrow. Rimiducid has been extensively studied in the context of haploidentical (partially matched) stem cell transplants. # Role in Haploidentical Transplants In haploidentical transplants, the donor is only a partial match to the recipient (often a parent, child, or sibling). This type of transplant carries a higher risk of Graft-versus-Host Disease (GvHD), where the donor cells attack the recipient’s body[19]. Researchers have developed a system where: 1. **T Cell Depletion**: The donor stem cell graft is depleted of certain T cells (TCR αβ+ T cells) that can cause GvHD. 2. **Addition of Modified T Cells**: The patient receives the donor’s stem cells along with donor T cells that have been genetically modified to include a rimiducid-responsive safety switch (these modified T cells are sometimes called rivogenlecleucel or BPX-501)[8]. 3. **Safety Monitoring**: If the patient develops GvHD despite the T cell depletion, rimiducid can be administered to eliminate the modified T cells and stop the GvHD[7]. This approach potentially allows patients to benefit from the positive effects of donor T cells (faster immune recovery, protection against infections, and anti-cancer effects) while providing a safety mechanism if GvHD occurs. Safety Profile and Side Effects Rimiducid itself appears to have a favorable safety profile, with most adverse events related to the underlying cellular therapy rather than the rimiducid administration. # Common Side Effects When rimiducid is administered, patients may experience: – **Fever**: A temporary increase in body temperature[1]. – **Chills**: Feeling cold and shivering despite normal or elevated body temperature[3]. – **Fatigue**: A feeling of tiredness or exhaustion[13]. – **Nausea**: An uncomfortable feeling in the stomach that may lead to vomiting[5]. These effects are generally mild and temporary, often resolving within a few hours or days after administration. # Intended Effects It’s important to understand that when rimiducid is administered, certain effects are actually intended: – **Reduction in modified cell numbers**: Rimiducid is designed to eliminate modified cells, so a decrease in their numbers is an expected and desired outcome[15]. – **Improvement in GvHD symptoms**: If rimiducid is given to treat GvHD, improvement in GvHD symptoms (such as skin rash, diarrhea, or liver dysfunction) indicates the medication is working properly[2]. # Special Considerations Patients receiving rimiducid should be aware that: – The medication is only effective against cells that have been specifically modified to include the safety switch. – After rimiducid administration, the beneficial effects of the modified cells (such as anti-cancer activity) may be reduced or lost[10]. – Close monitoring by healthcare providers is essential both before and after rimiducid administration. Current Research and Clinical Trials Rimiducid is being actively investigated in numerous clinical trials across various conditions and cellular therapy approaches. # Key Areas of Research Current research focuses on: 1. **Optimizing Dosing**: Studies are examining different doses of rimiducid (from 0.01 mg/kg to 0.4 mg/kg) to determine the optimal amount needed to control side effects while preserving some therapeutic benefits of the modified cells[20]. 2. **Expanding Applications**: Researchers are testing rimiducid-enabled safety switches in new types of cellular therapies, including: – Allogeneic (donor-derived) CAR-T cells for various cancers[17] – Natural Killer (NK) cell therapies for solid tumors[21] – T cell therapies for autoimmune diseases like lupus[14] 3. **Long-term Safety**: Studies are following patients for up to 15 years after receiving modified cells with rimiducid-responsive safety switches to monitor for any long-term effects[22]. # Notable Clinical Trials Some significant ongoing clinical trials involving rimiducid include: – **NCT06014762**: Investigating P-CD19CD20-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for B-cell malignancies[17]. – **NCT04960579**: Studying P-BCMA-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for multiple myeloma[16]. – **NCT05239143**: Examining P-MUC1C-ALLO1 CAR-T cells with rimiducid safety switch for advanced solid tumors[18]. – **NCT06984341**: Evaluating P-CD19CD20-ALLO1 for treatment-refractory systemic lupus erythematosus[14]. Future Directions The field of cellular therapy with built-in safety mechanisms is rapidly evolving, with rimiducid playing a central role in these innovations. # Emerging Applications Researchers are exploring several promising new applications for rimiducid-enabled safety systems: 1. **Autoimmune Disease Treatment**: Using modified T cells with safety switches to target and reset the immune system in diseases like lupus, multiple sclerosis, and rheumatoid arthritis[14]. 2. **Solid Tumor Therapies**: Developing more effective CAR-T and CAR-NK cell therapies for solid tumors with enhanced safety profiles through rimiducid-responsive switches[23]. 3. **Combination Approaches**: Integrating rimiducid-enabled safety mechanisms with other emerging technologies, such as: – Gene editing (CRISPR/Cas9) to create more precise cell modifications – Controllable activation systems to turn cellular therapies “on” and “off” as needed[18] # Patient Impact As research progresses, patients may benefit from: – **Wider Availability**: More centers offering cellular therapies with built-in safety mechanisms – **Expanded Eligibility**: More patients qualifying for these therapies due to improved safety profiles – **Outpatient Administration**: Some therapies potentially moving from inpatient to outpatient settings as safety improves[24] ### Challenges to Address Despite promising advances, several challenges remain: – **Cost**: Cellular therapies with advanced safety mechanisms are expensive to develop and administer – **Manufacturing Complexity**: Adding safety switches increases the complexity of producing modified cells – **Balancing Safety and Efficacy**: Finding the optimal approach to preserve therapeutic benefits while providing adequate safety controls[20] Rimiducid represents an important advancement in making cellular therapies safer and more controllable, potentially expanding their application to more patients and conditions in the future.
Category Details
Primary Function RIMIDUCID (AP1903) serves as a safety switch activator in genetically modified cell therapies, inducing apoptosis (cell death) in modified cells when severe side effects occur.
Main Clinical Applications – Controlling graft-versus-host disease (GVHD) after stem cell transplantation
– Managing cytokine release syndrome in CAR-T cell therapies
– Serving as a safety mechanism in various cellular immunotherapies
Patient Populations – Blood cancer patients (leukemia, lymphoma, myelodysplastic syndromes)
– Multiple myeloma patients
– Solid tumor patients (prostate, colorectal, etc.)
– Patients with non-malignant blood disorders
Cell Types Used With RIMIDUCID – BPX-501/Rivogenlecleucel (donor T cells with safety switch)
– Various CAR-T cell products targeting different antigens (BCMA, PSMA, CD19/CD20)
– Natural Killer (NK) cells with safety switches
Administration Method Intravenous infusion, typically at doses of 0.1-0.4 mg/kg depending on the protocol
Dosing Strategy Given as needed in response to severe treatment-related toxicity, not as a regular scheduled medication
Clinical Trial Phases Primarily being studied in Phase 1 and Phase 2 trials to establish safety, optimal dosing, and preliminary efficacy
Novel Applications – Allogeneic (off-the-shelf) CAR-T therapies
– Treatment of autoimmune conditions like systemic lupus erythematosus
– Solid tumor immunotherapies
Future Directions Integration with more cellular therapies to improve safety profiles and expand treatment options for patients with limited alternatives

FAQ

  • What is RIMIDUCID and how does it work? RIMIDUCID (also known as AP1903) is a medication that activates a 'safety switch' called inducible caspase 9 (iC9) which is engineered into cellular therapies. When administered, RIMIDUCID causes the modified cells to self-destruct through a process called apoptosis. This serves as a critical safety mechanism to control or eliminate these cells if they cause severe side effects like graft-versus-host disease (GVHD) in stem cell transplants or cytokine release syndrome in CAR-T cell therapies.
  • What conditions are being treated in clinical trials using RIMIDUCID? RIMIDUCID is being studied in clinical trials for multiple conditions, primarily: blood cancers (leukemia, lymphoma, myelodysplastic syndromes), multiple myeloma, solid tumors (like prostate cancer, colorectal cancer, and various advanced cancers), and non-malignant disorders (such as primary immunodeficiency, hemoglobinopathies, and metabolic disorders). It's always used in combination with cellular therapies as a safety measure, not as a standalone treatment.
  • What is graft-versus-host disease (GVHD) and how does RIMIDUCID help with it? Graft-versus-host disease (GVHD) is a serious complication that can occur after stem cell transplantation when the donor cells (graft) attack the recipient's tissues (host). It can affect the skin, liver, and digestive tract, ranging from mild to life-threatening. RIMIDUCID helps manage GVHD by activating the safety switch in the modified donor T cells, causing them to self-destruct when GVHD becomes severe or doesn't respond to standard treatments. This provides a rapid way to control the harmful immune response while preserving the benefits of the transplant.
  • Are there any side effects associated with RIMIDUCID itself? The clinical trials data indicates that RIMIDUCID is being studied specifically for its safety profile. The drug itself appears to have minimal direct side effects, as its primary function is to activate the engineered safety switch in modified cells. The main focus of safety monitoring in these trials is not on RIMIDUCID's direct effects, but rather on how effectively it controls the side effects caused by the cellular therapies, and whether it maintains the therapeutic benefits of those treatments.
  • How is RIMIDUCID different from conventional medications used in cancer treatment? Unlike conventional cancer medications that directly target cancer cells or broadly affect the immune system, RIMIDUCID works specifically on engineered therapeutic cells that have been given to patients. It doesn't directly treat the disease itself but serves as a safety mechanism for innovative cellular therapies. This represents a new paradigm in medicine where treatments come with built-in safety features that can be activated if needed. RIMIDUCID exemplifies the trend toward more precise, controllable therapies that can balance effectiveness with safety.

Ongoing Clinical Trials on RIMIDUCID

  • Study on the Safety of Anti-GD2 CAR T Cells, Cyclophosphamide, and Fludarabine in Children and Young Adults with Relapsed or Refractory Brain Tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of GD2-CAR T Cells, Cyclophosphamide, and Fludarabine for Children with High-Risk or Relapsed Neuroblastoma and Other GD2+ Tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Allogeneic Stem Cell Transplant: A procedure where a person receives blood-forming stem cells from a genetically similar, but not identical, donor. This is in contrast to an autologous transplant, where patients receive their own stem cells.
  • AP1903: The original name for rimiducid, a small molecule drug that activates the inducible caspase 9 safety switch in engineered cellular therapies.
  • BPX-501: A product name for genetically modified T cells (also called rivogenlecleucel) that contain the inducible caspase 9 safety switch which can be activated by rimiducid.
  • CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell therapy, a type of treatment that uses modified versions of a patient's own immune cells (T cells) to find and destroy cancer cells.
  • CaspaCIDe: The name for the safety switch technology using inducible caspase 9 that can be activated by rimiducid to eliminate engineered cells if needed.
  • Cytokine Release Syndrome (CRS): A systemic inflammatory response that can occur after certain immunotherapies, characterized by fever, low blood pressure, and respiratory difficulties. It's caused by a large, rapid release of cytokines into the blood from immune cells.
  • Dimerizer Drug: A type of drug (like rimiducid) that works by bringing two proteins together, which in this case activates the safety switch in engineered cells.
  • Dose Escalation Study: A clinical trial design where the dose of a drug is gradually increased to find the optimal balance between effectiveness and acceptable side effects.
  • Donor Lymphocyte Infusion (DLI): A procedure where lymphocytes (white blood cells) from the original stem cell donor are given to a patient who has already received a stem cell transplant, often to boost the immune response against cancer.
  • Graft Versus Host Disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant where the donor cells attack the recipient's tissues and organs. Symptoms can include skin rashes, liver problems, and digestive issues.
  • Graft Versus Leukemia (GVL) Effect: A beneficial effect where transplanted immune cells (the graft) recognize and attack leukemia cells in the recipient's body.
  • Haploidentical Transplant: A type of allogeneic transplant where the donor is a half-match (usually a parent, sibling, or child) with the recipient.
  • Hematopoietic Stem Cell Transplant (HSCT): A procedure that replaces damaged or destroyed blood-forming stem cells with healthy ones, used to treat various blood cancers and disorders.
  • Immune Reconstitution: The process by which the immune system rebuilds itself after treatments that have depleted immune cells, such as chemotherapy or stem cell transplantation.
  • Inducible Caspase 9 (iC9): An engineered protein that, when activated by rimiducid, triggers cell death (apoptosis). It serves as a safety switch in cell therapies.
  • Lymphodepletion: A procedure that reduces the number of lymphocytes in the body, often performed before cell therapies to create space for the infused therapeutic cells.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects, determined during dose escalation studies.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment, often below the level that can be detected with standard tests.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined from Phase 1 trials that will be used in Phase 2 trials, balancing efficacy and safety.
  • Relapse: The return of a disease after a period of improvement or remission.
  • Rivogenlecleucel: The generic name for BPX-501, which are donor T cells genetically modified with the inducible caspase 9 safety switch.
  • T Cell Depletion: The removal of T cells from a donor's stem cell graft to reduce the risk of graft-versus-host disease.
  • T Cell Receptor (TCR) Alpha Beta Depletion: A specific method of removing certain T cells (those with alpha beta receptors) from donor stem cell grafts to reduce the risk of GVHD while maintaining other beneficial cells.
  • T Stem Cell Memory (Tscm): A subset of T cells with enhanced ability to proliferate, persist, and generate various T cell types, making them valuable for cell therapies.

References

  1. https://clinicaltrials.gov/study/NCT02477878
  2. https://clinicaltrials.gov/study/NCT03301168
  3. https://clinicaltrials.gov/study/NCT02786485
  4. https://clinicaltrials.gov/study/NCT03639844
  5. https://clinicaltrials.gov/study/NCT03016377
  6. https://clinicaltrials.gov/study/NCT03807063
  7. https://clinicaltrials.gov/study/NCT03699475
  8. https://clinicaltrials.gov/study/NCT03733249
  9. https://clinicaltrials.gov/study/NCT03288493
  10. https://clinicaltrials.gov/study/NCT02743611
  11. https://clinicaltrials.gov/study/NCT04249947
  12. https://clinicaltrials.gov/study/NCT02744287
  13. https://clinicaltrials.gov/study/NCT02065869
  14. https://clinicaltrials.gov/study/NCT06984341
  15. https://clinicaltrials.gov/study/NCT03958656
  16. https://clinicaltrials.gov/study/NCT04960579
  17. https://clinicaltrials.gov/study/NCT06014762
  18. https://clinicaltrials.gov/study/NCT05239143
  19. https://clinicaltrials.gov/study/NCT01744223
  20. https://clinicaltrials.gov/study/NCT03459170
  21. https://clinicaltrials.gov/study/NCT07164469
  22. https://clinicaltrials.gov/study/NCT03741127
  23. https://clinicaltrials.gov/study/NCT06066424
  24. https://clinicaltrials.gov/study/NCT06358430